Should Men Take TRT? What the TRAVERSE Trial Actually Settled — and What It Didn’t

The tired, foggy 50-year-old asking whether he should take testosterone has been getting answers from three directions lately. Podcasters like Joe Rogan and Andrew Huberman tout it for energy, strength, and focus. The U.S. military began testosterone testing at annual checkups starting in July. And behind all of that sits the fear triad most guys carry quietly: prostate cancer, heart attacks, and steroids.

Here’s the thing about those fears. Each one traces back to a specific, dated study. And origin stories can be checked. According to Testosterone Clinics Florida, a directory that scored 150 TRT-related providers across Florida, the most common praise themes among clinics are knowledgeable staff and personalized treatment planning.

What low testosterone actually costs the body

For men with genuinely low testosterone, treatment improves muscle mass, workout recovery, fat mass, bone density, libido, sexual function, type 2 diabetes risk, fatigue, and depressive symptoms. Those benefits are scoped to diagnosed hypogonadism, not enhancement, and the starting point matters: testosterone isn’t just a sex hormone, it’s a metabolic one, touching muscle, fat distribution, bone density, red blood cells, insulin sensitivity, mood, focus, energy, sperm, and the heart.

The baseline every guy works against: levels decline roughly 1-2% per year after 30, so by your 50s you’re about a third below young-adult peaks, and by your 60s roughly half. Because it’s gradual, most men don’t notice until later. Untreated low testosterone is associated with more fat, less muscle, weaker bones, low mood, cognitive decline, and higher rates of cardiovascular death and death from any cause. Notably, low testosterone is independently associated with cardiovascular death.

Which reframes the whole question as risk versus risk, not risk versus benefit. Choosing to leave it untreated is a medical choice in its own right.

Does testosterone therapy increase prostate cancer risk?

Testosterone therapy does not meaningfully increase prostate cancer risk in men without pre-existing prostate disease. That’s the verdict, and it arrived despite decades of teaching that said otherwise.

Where the fear came from: in 1941, Charles Huggins showed that castration caused prostate tumors to regress. Medicine inferred the reverse, that testosterone must “feed” prostate cancer, and that single logical jump hung around in med-school curricula for the better part of a century. If your own doctor still flinches at TRT, that’s usually why.

The counter-idea is urologist Abraham Morgentaler’s saturation model. Prostate androgen receptors max out at roughly 200-250 ng/dL. Above that, added testosterone doesn’t meaningfully stimulate prostate growth. Think of a gas tank that’s already full: more pump does nothing. And the evidence backs it up. Pooled data across multiple studies has shown no significant uptick in prostate cancer diagnoses among men on TRT. Research published in JAMA Network Open and Nature questions the old links too, and the American Urological Association and Endocrine Society have updated their guidance to match.

That conditional half is where the honesty lives. Metastatic prostate cancer is an absolute no, full stop. Most men with treated low-grade localized cancer aren’t excluded after five or more years without recurrence, the line urologists associate with Marc Garnick’s threshold, though that data isn’t from randomized trials, so say it with the caveat attached. PSA monitoring at baseline and throughout is non-negotiable either way. But note what monitoring is: a different recommendation from categorical avoidance.

Do testosterone injections cause heart attacks or strokes?

Physiologic-dose replacement did not increase heart attacks, strokes, cardiovascular death, or prostate disease in the 2023 TRAVERSE trial, the largest randomized placebo-controlled test in men with low testosterone and pre-existing cardiovascular risk. Dr. Heidi Rayala is among the researchers whose work informs that conclusion.

Where the heart fear came from

A 2010 New England Journal of Medicine study was stopped early after men on testosterone had more cardiovascular events, and the headline scared everyone, doctors included. What got left out: the participants were older men with limited mobility, diabetes, and established heart disease. The study was small, stopped early, never designed to settle safety questions, and its results were stretched well past the data. The FDA compounded it in 2014 with a warning linking TRT to stroke, heart attack, and death.

What TRAVERSE proved, and what it didn’t

Proved: no significant increase in the major cardiovascular and prostate outcomes. Didn’t: the trial brought men from a baseline of 1-300 ng/dL up to only about 600, while real-world practice often targets 800-900. So TRAVERSE tested only modest replacement dosing, not supraphysiologic levels. The remaining risks deserve attention too: more cases of irregular heart rhythm, kidney impairment, and lung clots in the testosterone group, the kind of long-term safety data that’s essential context for anyone weighing TRT. Manageable, but they need an individual conversation, and Garnick suggests screening for underlying clotting predisposition.

Sources even disagree on follow-up length, with roughly 3-4 years on one account and under three on another; Peter Attia argues it would be premature to declare the debate settled, given that and the trial’s imperfect execution. Remember the inversion from earlier: untreated low testosterone is independently linked to cardiovascular death. Both directions carry risk.

Is TRT the same as anabolic steroids?

Same molecule, different dose and intent. And yes, testosterone is chemically an anabolic steroid either way, (“anabolic” is Greek for throwing upward), so conceding that up front is the only credible way to draw the real line. Steroid abuse typically involves supraphysiologic doses, frequently multiple compounds stacked together, without medical supervision. Replacement works to bring levels back to a normal physiologic range with calibrated dosing and a doctor watching. It’s the same distinction as a therapeutic corticosteroid script versus long-term high-dose harm: same drug family, wildly different use.

The counterweight matters more, though: giving testosterone replacement therapy to men with normal levels is the genuinely harmful scenario. Excess shuts down natural production, can hurt fertility, can worsen BPH and sleep apnea, and drives aggression along with elevated estradiol and DHT. As endocrinologist Margaret Wierman put it: Everybody feels better on testosterone. But is it safe? No, it’s not safe to give to men who are normal.

How do doctors diagnose low testosterone properly?

A proper diagnosis requires two separate fasting morning measurements below 300 ng/dL on a sensitive assay, plus symptoms, commonly at least three. No single draw settles it, partly because levels can swing up to 30% in a day and peak in the morning.

Why “in range” doesn’t settle it

The standard 300-1000 ng/dL reference comes from population averages that include ill, sedentary, and elderly men. Wierman notes the normal adult-male window is tighter, roughly 300-800, on sensitive mass-spectrometry testing. A 45-year-old at 310 ng/dL is technically normal and may feel terrible. The common evaluation gap follows a pattern: one total testosterone draw, told it’s in range, workup stops. No repeat morning draw, no free testosterone, no SHBG, no sleep apnea screen.

The real workup

Free testosterone is the fraction your body actually uses, and it can be low even when total testosterone reads normal. SHBG governs how much testosterone your tissues can grab, and as it climbs with age it drives most of the measured decline. LH and FSH, the pituitary signals that drive the testes, tell you where the problem lives, in the testicles or the signaling upstream. Symptoms count too.

Prevalence runs from under 1% of men under 30 to about 12% in their 50s, 20% in their 60s, 30% in their 70s, and roughly half in their 80s, but only about 6% of men across all ages meet the symptomatic criteria. For younger men weighing whether to start TRT at age 36, the calculus is different, fertility concerns and lifestyle-driven symptoms matter. Wierman’s closing position: “But normal is normal.” Men in range shouldn’t take it, however tempting the pitch.

What should be checked before starting TRT if symptoms have other causes?

Before any TRT decision, doctors should first check for conditions that push testosterone down as a secondary effect: obstructive sleep apnea, obesity, glucocorticoids like prednisone and cortisone shots, opioids, dietary supplements, pituitary tumors, and fatty liver disease, which alters SHBG. Sleep apnea deserves its own paragraph because it’s the most common hidden cause and the mechanism is concrete. Apnea raises cortisol and catecholamines, which drive central weight gain, higher blood pressure, reduced nitric oxide (hence erectile dysfunction), and slightly lowered testosterone through hypoxia. Treating the apnea often normalizes testosterone on its own. And TRT, conversely, can make sleep apnea worse, so starting testosterone with undiagnosed apnea is backwards.

Worth one line too: chronically short sleep can produce hypogonadism-like symptoms on its own. Fatigue, weight gain, low libido, and brain fog all have other suspects. Low testosterone is one of them, not the default answer.

What are the benefits of testosterone therapy for men?

In diagnosed hypogonadal men, TRT improves muscle mass, recovery, fat mass, bone density, libido, sexual function, type 2 diabetes risk, fatigue, and depressive symptoms. That scope is the whole point, which is why distinguishing age-related decline from clinical hypogonadism matters before considering treatment. Clinic marketing promises more: RegenCen, from the Cosmetic Skin & Laser Center (CSLC), targets “young-normal” levels of 800-1400 against the standard 300-1000 range, and its founder Dr. Gustav Lo, MD, reports roughly 90% of men feel better, but those are self-reported marketing figures, not clinical evidence, and Garnick expects fewer men to see dramatic improvement than the pitch implies.

What are the cons of TRT for men?

The main cons are blood thickening and clot risk, required prostate monitoring, fertility loss, and delivery-method-dependent supraphysiologic levels.

Delivery method is a safety decision, not a convenience decision

Wierman favors gels, lotions, and low-dose injections because you can adjust them quickly. Long-acting injections and pellets are the problem: they can push levels two to five times above normal for weeks or months. Her word was “scary,” and it’s the right word.

Monitoring and side effects

Testosterone raises hemoglobin and hematocrit, which thickens your blood and raises clot risk if nobody’s watching. Routine blood draws are part of the deal, the way oil changes are part of owning a turbo engine. There’s an open question about whether chronic marrow stimulation at supraphysiologic doses could contribute to polycythemia vera; unresolved, worth flagging, moving on. As color: an acquaintance of one patient’s donates blood monthly because his blood thickened on TRT, which tells you this isn’t hypothetical.

PSA and blood pressure monitoring are baseline requirements, and small PSA bumps on TRT have led Garnick’s patients to diagnoses of pre-existing cancer, an accidental early-warning system. Then there’s the ancillary-drug cascade: supraphysiologic doses create excess estrogen and DHT, the more potent androgen testosterone converts into, pushing patients onto aromatase inhibitors and finasteride, and post-finasteride syndrome, while rare, can be irreversible, including permanent libido loss. The attributed bottom line, from Dr. Kindred: TRT without close supervision is “a sure-fire risky approach.” Our fuller rundown of side effects of TRT in males covers the day-to-day stuff too.

Buyer rule: Skip pellets and long-acting injections as a starting point — adjustable gels or low-dose shots let your doctor dial levels back fast if bloodwork goes sideways.

Do men stay on TRT forever once they start?

For most men, yes, and the commitment is bigger than the daily dose. About two years of exogenous testosterone can permanently end the body’s own production and sperm generation. Recoverability depends on age at start and testicular reserve, and nobody can promise which side you land on. The concrete pattern that comes up in fertility discussions: men who start in their 20s often can’t conceive in their 30s.

The workaround people mention, Clomid or enclomiphene, preserves sperm production by raising FSH and LH, but it comes with its own tradeoffs: blocking estradiol’s effects in the brain may cost you the mood and libido benefits you started for, and long-term use raises DHEA, which carries possible atherosclerosis and cataract concerns. There’s an eerie precedent here, a DHEA-raising drug from the ’50s and ’60s that got pulled over cataracts and cardiovascular disease. Treat the workaround as unproven long-term, not as a free pass. The decision is one to make before starting, not discover after. More on that in whether men stay on TRT forever.

Are online TRT clinics safe compared to a regular doctor?

The safest TRT provider is the one where a physician who knows your baseline labs, symptoms, history, and goals makes small informed adjustments over time, and the telehealth model often fails that test. The failure mode, at the pattern level: one lab value, a standard dose, renewal every few months, and nobody tracking cardiovascular history or blood count trends. Telehealth operations like Hi, Finch Health sell the convenience, but clinicians including Dr. Kindred describe referred patients arriving with free testosterone around 35 ng/dL, roughly twice a reasonable level, often already on a stack of ancillary drugs. Attia’s concerns land here too: rising unsupervised use among young men, contamination from illegal sourcing, profit-driven prescribing. The critique isn’t of the therapy.

It’s of prescribing that never adjusts to how the patient actually responds. Good TRT is a process, not a transaction.

Red flag: One lab draw, one standard dose, automatic renewal every few months, and no one tracking your blood counts or cardiovascular history — walk away.

Can you take TRT after prostate cancer treatment?

For most men with treated low-grade localized prostate cancer who’ve been stable for five or more years, TRT isn’t flatly ruled out, it’s discussable with a physician. Metastatic disease is an absolute no. The regulatory arc shows how far things have moved: the FDA warned in 2014 about reports linking TRT to stroke, heart attack, and death; after TRAVERSE, it moved to drop that heart caution language and proposed a blood-pressure warning instead, and this year proposed dropping language saying TRT is unproven in age-related hypogonadism, which eases access and prescriber hesitancy. The proposed eligibility map: metastatic prostate cancer, no; low-grade localized, discuss with a physician; mild-to-moderate BPH, can consider; severe BPH, avoid. Practice has moved too: even post-prostatectomy patients get TRT, with PSA checked every 3 months and stopped on recurrence.

The honest limits stand: the supporting data isn’t from randomized trials, and short follow-up leaves decades-long prostate effects unknown for younger men. Context that reframes everything: TRT was first approved for men with little to no testosterone, Klinefelter’s disease or both testicles removed, based on restoring blood levels, not relieving symptoms. The evidence applies to women the same way: no data support an androgen deficiency syndrome in women, and the one proven postmenopausal use is HSDD, with a modest effect of about one additional satisfying sexual episode per month at high-normal premenopausal ranges. Wierman spoke at the FDA public meeting on testosterone in menopausal women on September 17, 2026.

The decision framework: who should take TRT

The answer to whether a man should take TRT is criteria-based, not age-based. No age-specific yes/no verdicts exist in the evidence. What exists is a sequence, and skipping steps is how guys end up on a drug stack they didn’t need.

1. Confirm the diagnosis properly. Two fasting morning draws below 300 ng/dL on a sensitive assay, plus symptoms, plus the full panel: free testosterone, SHBG, LH, FSH. One afternoon blood test after a bad week doesn’t qualify you.
2. Evaluate and treat underlying causes first. Sleep apnea, obesity, opioids, glucocorticoids, pituitary tumor, fatty liver. Low T is often the symptom, not the disease, and fixing the cause is cheaper than a lifetime of injections.
3. If treating, dose physiologically with a safety-ranked delivery method. Gels, lotions, and low-dose injections over pellets and long-acting injections, with a monitoring plan covering hematocrit, PSA, and blood pressure.
4. Understand the lifetime commitment and fertility consequences before starting. About two years can permanently end natural production and sperm generation. That conversation happens first.

Run the 45-year-old at 310 ng/dL through this framework. He’s technically normal, he may feel terrible, and the honest answer is that in-range men shouldn’t take it, even if he’s lower than his younger self. But it’s still worth exploring why he feels that way, because fatigue has other causes worth finding. TRAVERSE’s limited and disputed follow-up, and the unknown decades-long effects for younger men, belong in that conversation too. Garnick’s balanced close fits: he suspects fewer men than the marketing suggests will see dramatic improvement, but an informed trial after a risk discussion is reasonable.

And if you were told your levels are normal and you still don’t feel like yourself, the conversation is still worth having. Just have it with a doctor who knows your whole picture, not a renewal button.

Frequently Asked Questions